CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front
The Cancer Research Institute is shining a light on the explosive growth of cell therapies in the clinic, spotlighting China’s virtual overnight success in grabbing a lead role in the field. And they’re asking the world’s cancer drug development companies to adopt a new approach that will help the industry manage a finite number of potential trial patients while pointing researchers to the most likely avenue for doing something important — rather than just frittering away badly needed resources.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
